Status:
ACTIVE_NOT_RECRUITING
Post Marketing Surveillance of JARDIANCE in Chronic Kidney Disease
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Kidney Disease, Chronic
Eligibility:
All Genders
Brief Summary
Study objective is to investigate the safety and effectiveness of long-term daily use of JARDIANCE® Tablets in patients with chronic kidney disease under real-world use.
Eligibility Criteria
Inclusion
- Patients with CKD who are prescribed JARDIANCE® Tablets for CKD according to the current Japanese package insert and who provided written informed consent prior to enrolment in this study.
- Patients who have never been treated with JARDIANCE® Tablets (including treatment for Type 2 diabetes mellitus (T2DM) and/or chronic heart failure (CHF)) before enrolment.
Exclusion
- None
Key Trial Info
Start Date :
October 22 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 31 2027
Estimated Enrollment :
1027 Patients enrolled
Trial Details
Trial ID
NCT06527846
Start Date
October 22 2024
End Date
May 31 2027
Last Update
December 26 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nippon Boehringer Ingelheim Co., Ltd.
Tokyo, Japan, 1416017